

JEBS-25-12

Recasting *Listeria monocytogenes* from Pathogen to Therapeutic Ally: A Commentary

Elena Torrieri*

Independent researcher, UK

*Corresponding author: Elena Torrieri, Independent researcher, UK, E-mail: torrieri@gmail.com

Received date: November 26, 2025; Accepted date: December 12, 2025; Published date: December 26, 2025

Citation: Torrieri E (2025) Recasting *Listeria monocytogenes* from Pathogen to Therapeutic Ally: A Commentary. J Environ Biol Sci. Vol.1 No.2: 12.

Abstract

This commentary examines the recent preprint by Daula et al. on harnessing the virulence mechanisms of *Listeria monocytogenes* (Lm) for immunotherapeutic applications. The authors present a clear and well-integrated analysis of how Lm's intrinsic pathogenic traits particularly its capacity for intracellular invasion, phagosomal escape, and robust antigen presentation can be repurposed to elicit potent antitumor responses. Their review of attenuation strategies, including genetic deletions and killed-but-metabolically-active constructs, highlights progress toward developing safe yet immunogenic Lm-based vectors. The discussion is strengthened by incorporation of early clinical trial data demonstrating feasibility and preliminary efficacy in cancers such as HPV-related and HER2-positive malignancies. Although challenges persist including verification of long-term safety, tumor microenvironmental suppression, and manufacturing scalability the preprint contributes meaningfully to the development of bacterial immunotherapy platforms. This commentary situates the work within the broader landscape of next-generation cancer immunotherapy and outlines future directions critical for advancing Lm-based therapeutic strategies.

Keywords: *Listeria monocytogenes*; Cancer immunotherapy; Bacterial vectors; Attenuation; Tumor microenvironment; Immunogenicity; KBMA vaccines; Clinical translation

Introduction

The preprint by Daula et al., how virulence of *Listeria monocytogenes* can be harnessed to develop an immunotherapeutic agent, presents a timely and compelling exploration of how a classical foodborne pathogen might be repurposed as a powerful vector for cancer immunotherapy [1]. By examining the molecular foundations of *Listeria monocytogenes* (Lm) virulence and connecting these mechanisms to evolving clinical strategies, the authors effectively bridge fundamental microbiology with translational oncology. Their synthesis underscores an emerging perspective within the field: that certain pathogenic microorganisms possess attributes which, when properly engineered, could meaningfully transform future therapeutic modalities.

Major contributions and strengths

Clarity in mechanistic immunology

Daula et al. outline the most critical virulence factors Listeriolysin O (LLO), internalins, phospholipases, and ActA

and describe how these facilitate intracellular invasion, phagosomal escape, and cytosolic trafficking.

These processes allow Lm to activate both MHC class I and class II antigen presentation pathways, providing a rationale for its unusually strong induction of cytotoxic and helper T-cell responses. Such mechanistic clarity strengthens the rationale for Lm as a candidate vector for cancer immunotherapy.

Balanced discussion of safety and attenuation

Recognizing the inherent risks of using a pathogen in live-vector form, the authors review genetic attenuation approaches, including deletion of virulence genes, modulation of the PrfA regulatory network, and the creation of Killed-but-Metabolically-Active (KBMA) strains.

These strategies collectively preserve immunogenic potency while reducing pathogenicity, illustrating thoughtful consideration of the tradeoffs required for safe therapeutic design.

Emphasis on clinical advancement

Daula et al. integrate evidence from early clinical trials evaluating Lm-based immunotherapies in HPV-associated cancers, prostate cancer, and HER2-positive malignancies. Reports of acceptable safety profiles and preliminary signs of efficacy highlight the translational progress of this platform. The inclusion of human data demonstrates that Lm-based vectors have advanced beyond conceptual development into real-world therapeutic evaluation.

Illustration of therapeutic flexibility

The authors emphasize the versatility of Lm as a platform capable of delivering diverse tumor antigens and complementing other immunotherapies. Its potential compatibility with immune checkpoint inhibitors, adoptive T-cell therapies, and combination vaccination strategies suggests a highly adaptable role within next-generation oncology regimens (Figure 1).




Figure 1: Graphical abstract illustrating the conceptual transition of *Listeria monocytogenes* from a pathogenic organism to an engineered therapeutic vector. The left panel depicts the bacterium in its natural pathogenic role, highlighting intracellular invasion, phagosomal escape, and antigen presentation. The right panel illustrates its repurposed therapeutic function, emphasizing tumor targeting, immunotherapy activation, and safety-enhancing attenuation strategies.

Critical considerations and outstanding challenges

Persisting safety limitations

Despite promising attenuation strategies, even weakened Lm strains pose risks for immunocompromised patients. Long-term genomic stability, prevention of reversion to virulence, and limitation of horizontal gene transfer remain essential areas for scrutiny. Regulatory pathways for live microbial therapeutics will require

stringent demonstration of safety through comprehensive preclinical testing.

Tumor microenvironment as a barrier

Although Lm-based vectors evoke strong T-cell responses, the immunosuppressive microenvironment characteristic of many solid tumors may hinder their effectiveness. Future research should examine how these vaccines can be paired with microenvironment-modulating agents to overcome barriers posed by regulatory T cells, myeloid-derived suppressor cells, and checkpoint ligand expression.

Manufacturing and logistical constraints

Scaling attenuated Lm strains for clinical use entails significant manufacturing challenges, including batch consistency, stability assurance, and cold-chain logistics. These barriers must be addressed to enable reliable deployment of Lm-based vaccines at clinical and commercial scales.

Need for targeted patient selection

While the preprint highlights several cancer types tested in early trials, targeted patient selection strategies remain underdeveloped. Identification of biomarkers predictive of therapeutic response or toxicity will be essential for implementing precision Lm-based immunotherapy.

Broader implications for immunotherapy development

The conceptual framework provided by Daula et al. extends beyond *Listeria monocytogenes* itself, pointing toward a broader trend in microbial therapeutics. Lm's intracellular lifestyle, innate immunogenicity, and genetic tractability position it uniquely among potential microbial vectors for cancer therapy. Should safety and manufacturing challenges be resolved, Lm-based constructs may become integral elements of multimodal therapeutic strategies. Moreover, the emphasis on modular design including the ability to fine-tune virulence elements such as LLO or PrfA suggests a future in which bacterial vectors can be customized to match specific tumor antigens or patient immune profiles, contributing to the growing movement toward personalized immunotherapy.

Future research directions

Several promising areas of future exploration arise from the authors' analysis:

- **Preclinical safety and efficacy evaluation:** Expanded studies using immunocompromised and humanized models will be critical to assess long-term safety and durable immunological memory.

- **Combination therapeutic strategies:** Lm-based vectors could be synergistically paired with checkpoint blockade, metabolic modulators, or adoptive cell therapies to overcome tumor-mediated immunosuppression.
- **Biomarker development:** Identification of predictive biomarkers, such as antigen-specific T-cell signatures or cytokine profiles, will support patient selection and therapeutic optimization.
- **Improved manufacturing pipelines:** Establishing GMP-compliant production processes will facilitate reliable and scalable vaccine development.
- **Regulatory and ethical frameworks:** Early engagement with regulatory bodies and bioethics committees will help define safe, responsible pathways for clinical use of live microbial therapeutics.

Conclusion

Daula et al. present a thoughtful, forward-looking examination of how *Listeria monocytogenes* long recognized as a pathogen may be re-engineered into a therapeutic ally for cancer immunotherapy. Their synthesis of mechanistic insight, attenuation strategies, and early clinical evidence highlights a platform with substantial potential. Although challenges remain, the work provides a clear roadmap for advancing Lm-based immune therapeutics and contributes significantly to ongoing efforts to redefine the role of microbial agents in oncology.

References

1. Daula MM (2025) How virulence of *Listeria monocytogenes* can be harnessed to develop an immunotherapeutic agent.